MedTrace Logo

A Phase III Clinical Study of QY201 Tablet in Subjects With Moderate to Severe Atopic Dermatitis.

NCT07180511 · Status: ENROLLING_BY_INVITATION · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 460

Last updated 2025-09-18

No results posted yet for this study

Summary

To evaluate the efficacy of QY201 tablets in the treatment of adult patients with moderate to severe atopic dermatitis (AD).

Conditions

  • Atopic Dermatitis (AD)

Interventions

DRUG

10mg QY201 Placebo tablet

10mg QY201 Placebo tablet

DRUG

20mg QY201 Placebo tablet

20mg QY201 Placebo tablet

DRUG

10mg QY201 tablet

10mg QY201 tablet

DRUG

20mg QY201 tablet

20mg QY201 tablet

Sponsors & Collaborators

  • E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-12
Primary Completion
2027-05-18
Completion
2027-07-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07180511 on ClinicalTrials.gov